贵州省2014-2018年人感染H7N9禽流感病例流行病学调查分析

目的 了解贵州省Ｈ７Ｎ９禽流感病例的特征,为进一步防控提供参考。方法 收集贵州省2014-2018年人感染Ｈ７Ｎ９禽流感临床及流行病学疫情资料,用描述性流行病学方法分析其流行特征。结果 2014-2018年贵州省共确诊21例人感染H7N9人禽流感病例,死亡11例,病死率52.3%。以男性、中老年、农民为主,61.9%的病例发生在黔东南和黔南地区,2017年病例数占总病例数的80.9%,未发现聚集性疫情和二代病例。病例发现以不明原因肺炎监测发现为主,从暴露到发病、发病到首诊、发病到确诊、发病到抗病毒药物使用及发病到死亡的时间中位数分别为5天、3天、7天、7天和14天;有无基础性疾病的病死率差异无统计学意义（〖XC小五号.EPS;P〗=0.38,P=0.54）,后期病例病死率低于前期（〖XC小五号.EPS;P〗=4.24,P=0.04）。19例本地病例均有明确的活禽或活禽市场相关环境接触史,其中94.7%的活禽市场或活禽相关场所均检出H7核酸阳性,平均阳性率为32.3%(1.34%～82%),全面长期关闭活禽市场后疫情得到有效控制。 结论 接触活禽或活禽市场环境是感染的主要因素;加强活禽市场外环境监测,规范化管理及长期关闭活禽市场,可有效预警和控制疫情;加强基层医疗机构救治水平可有效降低病死率。     

江苏省镇江市2009-2018年15岁以下少年儿童法定报告传染病流行特征

目的 了解2009-2018年镇江市15岁以下少年儿童法定传染病的流行趋势,为开展防控工作提供依据。方法 从中国疾病预防控制信息系统中收集2009-2018年镇江市15岁以下少年儿童法定传染病疫情资料进行分析。结果 2009-2018年镇江市累计报告15岁以下少年儿童法定传染病病例22种65135例,年报告发病率134.51/万～263.23/万之间,发病率呈现上升波动趋势（〖XC小五号.EPS;P〗趋势=1932.389,P<0.001）;死亡病例12例,年均死亡率0.03/万;累计病例中男童发病数为38156例（58.58%）,年均发病率204.86/万;女童发病数为26979例（41.42%）,年均发病率159.81/万,不同性别间发病率差异有统计学意义（〖XC小五号.EPS;P〗=997.605,P<0.001）。无甲类传染病报告;乙类传染病累计报告病例16种2587例,年均发病率为7.29/万,发病呈下降趋势（〖XC小五号.EPS;P〗趋势=78.566,P<0.001）;丙类传染病累计报告病例6种62548例,年均发病率176.16/万,发病呈上升趋势（〖XC小五号.EPS;P〗趋势=2177.178,P<0.001）。肠道传染病、呼吸道传染病、血源及性传播传染病、自然疫源及虫媒传染病、其它传播途径传染病分别占累计发病总数的86.95%（56636例）、12.65%（8240例）、0.25%（166例）、0.03%（17例）、0.12%（76例）。发病率前2位的传染病为手足口病和流行性腮腺炎,分别占发病总数的78.43%（51088例）和8.42%（5485例）。结论 少年儿童是传染病发病的重点高危人群,应重点加强手足口病、流行性腮腺炎传染病的监测,采取针对性措施控制少年儿童传染病的发生。     

Isolated Systolic Hypertension and its Determinants - A Cross-sectional Study in the Adult Population of Lucknow District in North India

Objectives:

1) To determine the prevalence of isolated systolic hypertension (ISH) in the adult population of Lucknow district. 2) To study the determinants of ISH especially the relationship with age.

Materials and Methods:

A community-based cross-sectional study was conducted in four randomly selected areas of Lucknow district. A total of 800 subjects, aged 20 years and above, 400 from urban and 400 from rural area of Lucknow district were included in the study. The statistical tools used for analysis were Pearson''s Chi-square test and multiple logistic regression.

Results:

The prevalence of ISH according to JNC-7 criteria was 4.3%, which was 5.1% in men and 3.6% in women. A significant increase in the prevalence of ISH was seen with an increase in age. Multivariate logistic regression analysis of the determinants showed that age, BMI and smoking were significant independent risk factors of ISH.

Conclusions:

Given the risk of cardiovascular disease associated with ISH, the findings of this study emphasize the need for further research to document the impact of modifiable risk factors of ISH and the effect of hypertension screening and specific health promotion in bringing down the burden of ISH and related cardiovascular morbidity.     

Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists

Glucagon receptor antagonists have been actively pursued as potential therapeutics for the treatment of type 2 diabetes. Peptidyl and non-peptidyl glucagon receptor antagonists have been shown to block glucagon-induced blood glucose elevation in both animals and humans. How the antagonists and the glucagon receptor interact in vivo has not been reported and is the subject of the current study. Using (125)I-labeled glucagon as a radiotracer, we developed an in vivo glucagon receptor occupancy assay in mice expressing a human glucagon receptor in place of the endogenous mouse glucagon receptor (hGCGR mice). Using this assay, we first showed that the glucagon receptor is expressed predominantly in liver, to a much lesser extent in kidney, and is below detection in several other tissues/organs in the mice. We subsequently showed that, at 2 mg/kg body weight (mg/pk) dosed intraperitoneally (i.p.), peptidyl glucagon receptor antagonist des-His-glucagon binds to approximately 78% of the hepatic glucagon receptor and blocks an exogenous glucagon-induced blood glucose elevation in the mice. Finally, we also showed that, at 10 and 30 mg/kg dosed orally (p.o.), compound A, a non-peptidyl small molecule glucagon receptor antagonist, occupied 65-70% of the hepatic glucagon receptor, and significantly diminished exogenous glucagon-induced blood glucose elevation in the mice. At 3 mg/kg, however, compound A occupied only approximately 39% of the hepatic glucagon receptor and did not affect exogenous glucagon-induced blood glucose elevation in the mice. Taken together, the results confirmed previous reports that glucagon receptors are present predominantly in the liver, and provide the first direct evidence that peptidyl and non-peptidyl glucagon receptor antagonists bind to the hepatic glucagon receptor in vivo, and that at least 60% receptor occupancy correlates with the glucose lowering efficacy by the antagonists in vivo.     

西立伐他汀和普伐他汀治疗高胆固醇血症患者疗效比较

目的 :探讨西立伐他汀及普伐他汀对高胆固醇血症患者疗效及安全性。方法 :15 0例高胆固醇血症患者随机分为两组 :西立伐他汀组 75例和普伐他汀组 75例 ,治疗 8周后观察血脂变化和安全性 ,并加以比较。结果 :两种药物均可显著降低总胆固醇 (TC) ,血甘油三酯 (TG) ,低密度脂蛋白 胆固醇 (LDL C) ,并可升高高密度胆蛋白 胆固醇 (HDL C) ,而两药的不良反应无显著差异。结论 :西立伐他汀具有显著的降脂作用 ,在调脂的同时并可抑制血小板活性 ,改善胰岛素抵抗。     

Neonatal fat embolism and agglutination of intralipid

Pulmonary fat embolism in a preterm infant receiving Intralipid intravenously is described. Serum obtained at the time of clinical deterioration agglutinated Intralipid. This coincided with the onset of septicaemia and with a raised serum C reactive protein concentration. Subsequent clinical improvement was associated with reduction in the C reactive protein concentration and nonagglutination of Intralipid.     

促性腺激素释放多肽(GRP)对体外培养小鼠垂体分泌LH的影响

合成的促性腺激素释放多肽(GRP)及其类似物GRp～NH₂,[Glu^7.9.14Lys^6.10]GRP(6～14),[phe¹⁴]GRP(5～14)和[phe¹⁴]GRP浓度在0.05mmol·L^-1时,具有刺激体外培养的小鼠垂体分泌LH的作用。其活性依此相当对照垂体的115.4,114.2,140,160和179%。小鼠于妊振第7～9天或第1～5天,每只sc[phe¹⁴]GRP1mg·d^-1,或于妊娠第2～4天每只sc[phe¹⁴]GRP(5～14)1mg·d^-1,有40～60%的妊娠动物出现死胎。     

左旋18-甲基炔诺酮肟与左旋18-甲基炔诺酮的抗生育作用比较

本文比较了LNGO和LNG对大鼠的抗生育作用,结果表明,LNGO在剂量为10mg/kg·d时可以完全抑制大鼠着床,剂量为40,60mg/kg·d时有明显抗早孕作用。光电镜观察提示,剂量为10mg/kg·d时,对大鼠子宫内膜间质细胞和上皮细胞均有影响。组织培养研究发现,对体外人胎盘滋养层细胞有直接损伤作用。LNG对大鼠未见抗着床及抗早孕作用,对大鼠子宫内膜和体外人胎盘滋养层细胞也均未见明显作用。     

Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells

Somatostatin (SRIH) regulates pituitary adrenocorticotropin (ACTH) secretion by interacting with a family of homologous G protein-coupled membrane receptors. The SRIH receptor subtypes (sst(1)-sst(5)) that control ACTH release remain unknown. Using novel, subtype-selective SRIH analogs, we have identified the SRIH receptor subtypes involved in regulating ACTH release from AtT-20 cells, a model for cell line pituitary corticotropes. Radioligand-binding studies with (125)I-SRIH-14 and (125)I-SRIH-28 showed that SRIH-14 and SRIH-28 recognized specific, high-affinity and saturable membrane-binding sites. Nonpeptidyl agonists with selectivity for the sst(2) (L-779,976; compound 2) or sst(1)/sst(5)) (L-817,818; compound 5) receptor subtypes potently displaced (125)I-SRIH-28 from AtT-20 cell membranes, while agonists selective for the sst(1) (L-779,591; compound 1), sst(3) (L-796,778; compound 3) or sst(4) (L-803,087; compound 4) subtypes were inactive. Tyr(11)-SRIH-14, compound 2 (sst(2)) or compound 5 (sst(5)) inhibited forskolin and corticotropin-releasing hormone (CRH)-induced increases in intracellular cAMP. Furthermore, the sst(2) and sst(5) agonists potently inhibited CRH-induced ACTH release from AtT-20 cells. These results provide the first evidence that sst(2) and sst(5) receptor subtypes, but not sst(1), sst(3) or sst(4), inhibit cAMP accumulation and regulate ACTH secretion in the AtT-20 cell model of the rodent corticotrope.